U.S. Neurodegenerative Disease Market Size, Share & Forecast 2026–2032

ID: MR-11212 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Neurodegenerative Disease Market
  • ✓Market Size 2024: USD 14.8 billion
  • ✓Market Size 2032: USD 27.6 billion
  • ✓CAGR: 8.1%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Blood Tests Gate Access: Fujirebio's plasma pTau217 assay, cleared by the FDA in 2025, is moving amyloid screening from PET scanners into routine blood draws. Quest Diagnostics and Labcorp now control the lab channel that determines which patients reach Leqembi and Kisunla.
FINDING 02
Parkinson's Volume Beats Amyloid: Consensus treats anti-amyloid antibodies as the market's growth engine, yet generic carbidopa-levodopa from Teva and Amneal still dominates Parkinson's prescription volume. Disease-modifying entrants will face the same price erosion as Medicare negotiation under the Inflation Reduction Act expands.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Lab Channel Partnerships: Diagnostics vendors and anti-amyloid sponsors should secure multiyear partnerships with Quest Diagnostics or Labcorp before the end of 2026. Blood-based pTau217 testing volume will decide which therapy captures Medicare-covered patients through 2028, so early channel exclusivity locks in share.

Competitive Overview: Neurodegenerative Drugs in the United States

The U.S. neurodegenerative market is concentrated at the top and fragmented beneath it. Eli Lilly, Biogen, Eisai, and Genentech control most branded disease-modifying revenue, while Teva and AbbVie anchor symptomatic and movement-disorder franchises. Device and diagnostics segments remain fragmented, with Medtronic and Abbott competing in deep brain stimulation. Most leaders are American-headquartered, though Eisai and Genentech run U.S. operations through Japanese and Swiss parents, so domestic commercial execution decides share.

Competitive advantage in the United States rests on three factors: Medicare reimbursement strategy, specialist neurology reach, and diagnostic pathway integration. Anti-amyloid therapies require confirmed pathology through PET or plasma biomarkers, plus MRI monitoring for amyloid-related imaging abnormalities. Firms that secure hospital and imaging partnerships therefore outperform rivals with superior trial data alone. Payers now demand real-world outcome evidence before granting coverage, which rewards registry investment.

Demand Drivers Shaping Neurodegenerative Care in America

Population aging is the foundational driver. Roughly one million Americans live with Parkinson's disease, and nearly seven million aged 65 and older live with Alzheimer's dementia. Biogen and Eisai gain most from this volume because Leqembi's infusion-center footprint scales with diagnosed cohorts, while Teva's generic carbidopa-levodopa franchise captures the symptomatic baseline. Diagnosed cohorts are growing fastest among patients aged 75 and older, the group that anchors infusion demand.

Anti-amyloid approvals constitute the second driver. Eli Lilly's Kisunla, approved by the FDA in July 2024, entered a market where Leqembi already held traditional approval, creating two-brand competition in infusion therapy. Lilly benefits from a finite dosing duration that lowers lifetime cost per patient. Huntington's chorea adds a third driver, where Teva's Austedo and Neurocrine's Ingrezza sustain a duopoly in VMAT2 inhibitors.

Competitive Restraints and Market Challenges

Price competition is intensifying as Medicare negotiation under the Inflation Reduction Act extends to high-spend drugs. Biogen withdrew Aduhelm in 2024 after weak uptake, showing that payer scrutiny and CMS coverage-with-evidence-development requirements can erase a launch. Generic carbidopa-levodopa keeps symptomatic pricing deflationary, squeezing mid-tier brands that lack differentiated formulations. Commercial payers increasingly mirror federal prior-authorization rules, adding administrative cost to each infusion.

Talent and infrastructure gaps constrain competitors more than price. Neurologist supply is thin outside metropolitan areas, and many rural counties lack a board-certified neurologist for diagnosis or treatment initiation. Infusion capacity and MRI scanners are concentrated in academic medical centers, which limits how quickly anti-amyloid therapies can scale to community practices and slows return on field-force investment. Staffing shortages also raise infusion nursing costs.

Growth Opportunities for Market Players

Blood-based biomarker testing represents the largest near-term opening. Fujirebio's plasma pTau217 assay, cleared by the FDA in 2025, lets primary care physicians triage patients before referral, and Quest Diagnostics and Labcorp are positioned to scale that volume through existing draw networks. C2N Diagnostics and Quanterix target the same funnel with mass-spectrometry and digital immunoassay platforms, rewarding companies that embed testing into electronic health record workflows.

Neuromodulation and digital monitoring form the second opportunity. Medtronic and Abbott supply deep brain stimulation systems for advanced Parkinson's, and Medtronic's BrainSense adaptive DBS received FDA approval in 2025, rewarding device specialists who secure reimbursement. Biogen's Qalsody, the first tofersen therapy for SOD1-linked ALS approved in 2023, opens a rare-disease niche where orphan pricing and genetic testing partnerships determine patient access.

Market at a Glance

MetricValue
Market Size 2024USD 14.8 billion
Market Size 2032USD 27.6 billion
Growth Rate (CAGR)8.1%
Most Critical Decision FactorPayer reimbursement access and diagnostic pathway integration
Largest RegionSouth (largest patient population)
Competitive StructureOligopolistic in disease-modifying therapies; fragmented in devices and diagnostics

Leading Market Participants

  • Eli Lilly and Company
  • Biogen
  • Eisai
  • Genentech
  • AbbVie
  • Teva Pharmaceutical Industries
  • Neurocrine Biosciences
  • Medtronic
  • Quest Diagnostics
  • Fujirebio

Regulatory and Policy Environment

The FDA's accelerated approval pathway, used for Aduhelm in 2021, now carries higher evidentiary standards following Aduhelm's 2024 withdrawal. Leqembi and Kisunla secured traditional approvals, and the agency's breakthrough and fast-track designations shape which sponsors reach the market first. The FDA cleared Fujirebio's plasma assay in 2025 as an aid for amyloid pathology, creating a regulatory template that diagnostics competitors must now follow.

CMS coverage with evidence development requires anti-amyloid antibody recipients to enroll in a national registry, adding administrative burden that favors large sponsors. The Inflation Reduction Act introduced Medicare price negotiation and capped Part D out-of-pocket spending at $2,000 in 2025, reshaping oral and symptomatic drug economics. The National Alzheimer's Project Act coordinates federal research funding through the NIH, sustaining the pipeline of new entrants.

Competitive Outlook for Neurodegenerative Drugs in America

By 2032, competition will shift from drug efficacy toward diagnostic throughput and payer evidence. Eli Lilly and Eisai will contest the anti-amyloid franchise through subcutaneous maintenance dosing and expanded primary care screening, while Biogen defends its installed base through its ALS and neuroimmunology portfolio. AbbVie's acquisition of Cerevel Therapeutics in 2024 signals that large pharma will buy late-stage neuroscience assets rather than build them.

Symptomatic Parkinson's and Huntington's markets will consolidate around generics and branded VMAT2 and dopamine specialists, compressing margins. Diagnostics leaders with clinician reach, including Quest Diagnostics, Labcorp, and Fujirebio, will capture a growing share of value as testing precedes treatment. Companies without a diagnostic pathway or a Medicare evidence strategy will exit the disease-modifying segment by the end of the forecast period.

Frequently Asked Questions

Eli Lilly, Biogen, and Eisai lead anti-amyloid franchises, while Teva and Neurocrine dominate movement-disorder revenue. Genentech and AbbVie hold significant positions across neurology portfolios.
Most leading firms are U.S.-headquartered, while Eisai and Genentech compete through Japanese and Swiss parent structures. Share is determined by domestic commercial execution, payer access, and specialist reach.
Medicare reimbursement strategy, specialist neurology access, and diagnostic pathway integration determine competitive position. Companies with imaging and infusion partnerships consistently outperform rivals with stronger trial data alone.
Medicare negotiation under the Inflation Reduction Act pressures pricing for high-spend drugs and rewards companies with diversified portfolios. Mid-tier symptomatic brands face the greatest margin compression from generic competition.
Eli Lilly and Biogen are best positioned in disease-modifying therapies, supported by subcutaneous and maintenance dosing strategies. Quest Diagnostics, Labcorp, and Fujirebio are positioned to capture growing diagnostic value.

Market Segmentation

By Disease Indication
  • Alzheimer's Disease
  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington's Disease
  • Frontotemporal Dementia
By Therapy Type
  • Disease-Modifying Therapies
  • Symptomatic Medications
  • Neuromodulation Devices
  • Diagnostic Assays
By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Infusion Centers
  • Retail Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Neurodegenerative Disease Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Disease Indication Insights
4.1 Alzheimer's Disease
4.2 Parkinson's Disease
4.3 Amyotrophic Lateral Sclerosis
4.4 Huntington's Disease
4.5 Others
Chapter 05 Therapy Type Insights
5.1 Disease-Modifying Therapies
5.2 Symptomatic Medications
5.3 Neuromodulation Devices
5.4 Diagnostic Assays
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Hospital Pharmacies
6.2 Specialty Pharmacies
6.3 Infusion Centers
6.4 Retail Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Eli Lilly and Company
7.2.2 Biogen
7.2.3 Eisai
7.2.4 Genentech
7.2.5 AbbVie
7.2.6 Teva Pharmaceutical Industries
7.2.7 Neurocrine Biosciences
7.2.8 Medtronic
7.2.9 Quest Diagnostics
7.2.10 Fujirebio
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.